Immuno-Oncology Cell Therapy Market Size, Share & Trends Analysis Report By Therapy Type (CAR-T Cells, NK & NKT Cells, TAA/TSA targeted T Cell, TCR T Cell, and Other Cell Therapies), By Cell Source, By Indication Type, By Region, And Segment Forecasts, 2025-2034
Global Immuno-oncology Cell Therapy Market Segmentation
Global Immuno-oncology Cell Therapy Market Outlook 2021-2034 by Therapy Type
- CAR-T Cells
- Kymriah
- Yescarta
- Tecartus
- Breyanzi
- Carvykti
- Abecma
- Others
- NK & NKT Cells
- TAA/TSA targeted T Cell
- TCR T Cell
- Cytokine-induced killer Cells
- Dendritic Cells
- Macrophages
- Other Cell Therapies
Global Immuno-oncology Cell Therapy Market Outlook 2021-2034 by Major Indication
- Head & Neck Cancer
- Lung Cancer
- Kidney Cancer
- Melanoma
- Lymphoma
- Leukemia
- Others
By Cell Source
- Autologous
- Allogeneic
- iPSC-derived Universal Cells
Global Immuno-oncology Cell Therapy Market Outlook 2021-2034 by Region
- North America
- Asia-Pacific
- Europe
- Latin America
- Middle-East& Africa
Europe Immuno-oncology Cell Therapy Market Outlook 2021-2034 by Country
- UK.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
North America Immuno-oncology Cell Therapy Market Outlook 2021-2034 by Country
- US.
- Canada
Asia Pacific Immuno-oncology Cell Therapy Market Outlook 2021-2034 by Country
- India
- China
- Japan
- South Korea
- Australia & New Zealand
Latin America Immuno-oncology Cell Therapy Market Outlook 2021-2034 by Country
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa Immuno-oncology Cell Therapy Market Outlook 2021-2034 by Country
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Immuno-oncology Cell Therapy Market Snapshot
Chapter 4. Global Immuno-oncology Cell Therapy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis of Key Immuno-oncology Cell Therapy Industry
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Clinical Trial/Pipeline Analysis 2021
4.8. COVID-19 Impact on Oncology Industry
Chapter 5. Market Segmentation 1: Therapy Type Estimates & Trend Analysis
5.1. Therapy Type & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Therapy Type:
5.2.1. CAR-T Cells
5.2.2. NK & NKT Cells
5.2.3. TCR T Cells
5.2.4. TAA/TSA targeted T Cell
5.2.5. Cytokine-induced killer cells
5.2.6. Dendritic cells
5.2.7. Macrophages
5.2.8. Other Cell Therapies
Chapter 6. Market Segmentation 2: Indication Type Estimates & Trend Analysis
6.1. Indication Type & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication Type:
6.2.1. Head & Neck Cancer
6.2.2. Lung Cancer
6.2.3. Kidney Cancer
6.2.4. Melanoma
6.2.5. Lymphoma
6.2.6. Leukemia
6.2.7. Others
Chapter 7. Immuno-oncology Cell Therapy Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Immuno-oncology Cell Therapy Market revenue (US$ Million) estimates and forecasts by Therapy Type, 2021-2034
7.1.2. North America Immuno-oncology Cell Therapy Market revenue (US$ Million) estimates and forecasts by Indication Type, 2021-2034
7.1.3. North America Immuno-oncology Cell Therapy Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
7.1.3.1. U.S.
7.1.3.2. Canada
7.2. Europe
7.2.1. Europe Immuno-oncology Cell Therapy Market revenue (US$ Million) by Therapy Type, 2021-2034
7.2.2. Europe Immuno-oncology Cell Therapy Market revenue (US$ Million) estimates and forecasts by Indication Type, 2021-2034
7.2.3. Europe Immuno-oncology Cell Therapy Market revenue (US$ Million) by country, 2021-2034
7.2.3.1. Germany
7.2.3.2. Poland
7.2.3.3. France
7.2.3.4. Italy
7.2.3.5. Spain
7.2.3.6. UK
7.2.3.7. Rest of Europe
7.3. Asia Pacific
7.3.1. Asia Pacific Immuno-oncology Cell Therapy Market revenue (US$ Million) by Therapy Type, 2021-2034
7.3.2. Asia Pacific Immuno-oncology Cell Therapy Market revenue (US$ Million) estimates and forecasts by Indication Type, 2021-2034
7.3.3. Asia Pacific Immuno-oncology Cell Therapy Market revenue (US$ Million) by country, 2021-2034
7.3.3.1. China
7.3.3.2. India
7.3.3.3. Japan
7.3.3.4. Australia
7.3.3.5. Rest of Asia Pacific
7.4. Latin America
7.4.1. Latin America Immuno-oncology Cell Therapy Market revenue (US$ Million) by Therapy Type, 2021-2034
7.4.2. Latin America Immuno-oncology Cell Therapy Market revenue (US$ Million) estimates and forecasts by Indication Type, 2021-2034
7.4.3. Latin America Immuno-oncology Cell Therapy Market revenue (US$ Million) by country, (US$ Million) 2021-2034
7.4.3.1. Brazil
7.4.3.2. Rest of Latin America
7.5. Middle East & Africa
7.5.1. Middle East & Africa Immuno-oncology Cell Therapy Market revenue (US$ Million) by Therapy Type, (US$ Million)
7.5.2. Middle East & Africa Immuno-oncology Cell Therapy Market revenue (US$ Million) estimates and forecasts by Indication Type, 2021-2034
7.5.3. Middle East & Africa Immuno-oncology Cell Therapy Market revenue (US$ Million) by country, (US$ Million) 2021-2034
7.5.3.1. South Africa
7.5.3.2. GCC Countries
7.5.3.3. Rest of MEA
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Novartis
8.2.2. Juno Therapeutics
8.2.3. Agios Pharmaceutical
8.2.4. Adicet Bio, Inc.
8.2.5. Adaptimmune Therapeutics plc.
8.2.6. Atara Biotherapeutics
8.2.7. Artiva Biotherapeutics, Inc.
8.2.8. Shenzhen BinDeBio Ltd.
8.2.9. Editas Medicine
8.2.10. China Immunotech Co., Ltd.
8.2.11. CRISPR Therapeutics
8.2.12. Lion TCR
8.2.13. Autolus Limited
8.2.14. Kite Pharma
8.2.15. Bellicum Pharmaceuticals
8.2.16. bluebird bio
8.2.17. Calibr
8.2.18. Carina Biotech
8.2.19. CARsgen Therapeutics
8.2.20. Celgene Corporation
8.2.21. Cellectis
8.2.22. Cell Medica
8.2.23. Allogene Therapeutics
8.2.24. Amgen
8.2.25. Cell Design Labs
8.2.26. Celularity
8.2.27. Celyad
8.2.28. Eureka Therapeutics
8.2.29. Fate Therapeutics
8.2.30. Fortress Bio
8.2.31. Gilead Sciences
8.2.32. Immatics US Inc.
8.2.33. Immunocore
8.2.34. Sorrento Therapeutics, Inc.
8.2.35. Janssen Biotech
8.2.36. JW Therapeutics
8.2.37. Kleo Pharmaceuticals
8.2.38. Medisix Therapeutics
8.2.39. Mustang Bio
8.2.40. Medigene
8.2.41. NantKwest
8.2.42. Nanjing Legend Biotech
8.2.43. Precision Biosciences
8.2.44. Posedia Therapeutics
8.2.45. T-Cure Biosciences Inc
8.2.46. TCR2 Therapeutics
8.2.47. T-knife
8.2.48. TScan Therapeutics
8.2.49. Triumvira Immunologics USA, Inc.
8.2.50. Ziopharm
8.2.51. Zelluna Immunotherapy
8.2.52. 3T Biosciences, Inc.
8.2.53. Other Prominent Players
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Global Immuno-Oncology Cell Therapy Market Size is valued at USD 11.9 Billion in 2024 and is predicted to reach USD 95.3 Billion by the year 2034
Global Immuno-Oncology Cell Therapy Market is expected to grow at a 23.2% CAGR during the forecast period for 2025-2034
Novartis, Juno Therapeutics, Agios Pharmaceutical, Atara Biotherapeutics, Shenzhen BinDeBio Ltd., China Immunotech Co., Ltd., Autolus Limited, Kite Ph
By Therapy Type, By Indication Type, By Cell Source are the key segments of the Immuno-Oncology Cell Therapy Market.
North American region is leading the Immuno-Oncology Cell Therapy Market.